Shmt2: A Stat3 Signaling New Player in Prostate Cancer Energy Metabolism

Ilaria Marrocco1, Fabio Altieri2, Elisabetta Rubini3

  • 1Department of Biochemical Sciences "A. Rossi Fanelli" and Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University, P.le A. Moro 5, 00185 Rome, Italy. ilaria.marrocco@weizmann.ac.il.

Cells
|September 11, 2019
PubMed

Insights

This study reveals a STAT3 signaling loop involving SHMT2 and PKM2 that drives metabolic shifts in prostate cancer (PCa). This pathway contributes to cancer progression and may link inflammation to more aggressive phenotypes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Prostate cancer (PCa) involves complex regulatory pathways, with STAT3 protein influencing metabolic enzymes.
  • STAT3 activation is linked to aberrant metabolic activity in cancer cells, including the Warburg effect.

Purpose of the Study:

  • To investigate the role of the STAT3 pathway and its interaction with SHMT2 in prostate cancer progression.
  • To elucidate the molecular mechanisms linking inflammation, metabolic reprogramming, and PCa aggressiveness.

Main Methods:

  • Bioinformatic analysis to identify STAT3 binding sites on the SHMT2 gene.
  • In vitro studies using LNCaP cells (PCa cell line) to examine JAK2/STAT3 pathway activation and SHMT2 expression.
  • Analysis of FFPE prostate tissue sections from patients with varying Gleason scores.

Main Results:

  • IL-6 stimulation upregulated SHMT2 expression via the JAK2/STAT3 pathway in LNCaP cells.
  • SHMT2 activation decreased serine levels, promoting nuclear PKM2 translocation and non-canonical STAT3 activation, leading to a shift towards anaerobic metabolism.
  • A STAT3/SHMT2/PKM2 loop was identified in early-stage PCa, while a STAT3/HIF-1α/PKM2 loop maintained the Warburg effect in aggressive PCa.

Conclusions:

  • The STAT3/SHMT2/PKM2 loop mediates metabolic shifts in response to inflammation during early PCa.
  • Chronic inflammation may promote PCa progression through STAT3-mediated metabolic reprogramming.
  • SHMT2 is a potential key factor in understanding the transition to aggressive prostate cancer phenotypes.

Related Concept Videos

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases13:18

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases

Here we explain a protocol for modelling the biophysical microenvironment where crosslinking and increased stiffness of the basement membrane (BM) induced by advanced glycation endproducts (AGEs) has pathological...
10.1K
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult...
14.6K
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

This protocol provides a comprehensive procedure to isolate, expand, and immortalize fibroblasts from radical prostatectomies. Moreover, it describes assays developed to assess the functional effects of fibroblast-tumor cell crosstalk, taking advantage of both treatment with conditioned medium and...
746
Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model05:07

Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model

In this video, we demonstrate the procedure for administering intra-prostatic injection of prostate cancer cells into a mouse model. Orthotopic murine models can be used to study the disease origin and response to treatment therapies in a non-invasive and clinically relevant...
5.6K